甘精胰岛素与中效人胰岛素治疗老年2型糖尿病疗效及安全性比较
|
摘要
目的比较甘精胰岛素与中效人胰岛素治疗老年2型糖尿病的临床疗效及安全性。方法 60例老年2型糖尿病患者,随机分为对照组与观察组,各30例。对照组给予中效人胰岛素进行治疗,观察组给予甘精胰岛素进行治疗。对比两组治疗前后空腹血糖(FPG)、餐后血浆血糖(PPG)水平;血糖达标时间、胰岛素日用量以及低血糖事件发生情况。结果治疗前,观察组FPG、PPG水平分别为(9.19±1.24)、(16.35±3.58)mmol/L,对照组FPG、PPG水平分别为(9.22±1.19)、(16.21±3.64)mmol/L,对比差异无统计学意义(P>0.05)。治疗后,观察组FPG、PPG水平分别为(5.98±1.04)、(9.41±1.58)mmol/L,对照组FPG、PPG水平分别为(6.23±0.92)、(9.57±1.67)mmol/L;两组FPG、PPG水平均低于本组治疗前,差异具有统计学意义(P<0.05);两组FPG、PPG水平对比,差异无统计学意义(P>0.05)。观察组血糖达标时间(2.81±0.26)d短于对照组的(3.24±0.64)d,胰岛素日用量(0.65±0.07)IU/kg少于对照组的(0.79±0.06)IU/kg,低血糖事件发生率13.33%低于对照组的43.33%,差异均具有统计学意义(P<0.05)。结论甘精胰岛素与中效人胰岛素均可有效地控制老年2型糖尿病患者的血糖,因前者低血糖发生率低、胰岛素用量较少、血糖达标时间短,老年2型糖尿病患者更受益。
Objective To compare the clinical efficacy and safety of insulin glargine and intermediateacting human insulin in the treatment of type 2 diabetes in the elderly. Methods A total of 60 elderly patients with type 2 diabetes were randomly divided into control group and observation group, with 30 cases in each group. The control group was treated with intermediate-acting human insulin, and the observation group was treated with insulin glargine. Comparison were made on fasting plasma glucose(FPG) and postprandial 2 h plasma glucose(PPG) before and after treatment, the time of blood glucose reaching the standard, the daily dosage of insulin and the occurrence of hypoglycemia events between the two groups. Results Before treatment, the observation group had FPG and PPG level respectively as(9.19±1.24) and(16.35±3.58) mmol/L, which were(9.22±1.19) and(16.21±3.64) mmol/L in the control group, and the difference was not statistically significant(P>0.05). After treatment, the observation group had FPG and PPG level respectively as(5.98±1.04) and(9.41±1.58) mmol/L, which were(6.23±0.92) and(9.57±1.67) mmol/L in the control group. Both groups had lower FPG and PPG than those before treatment, and the difference was statistically significant(P<0.05). There was no statistically significant difference in FPG and PPG(P>0.05). After treatment, the observation group had shorter time of blood glucose reaching standard as(2.81±0.26) d than(3.24±0.64) d in the control group, less daily dosage of insulin as(0.65±0.07) IU/kg than(0.79±0.06) IU/kg in the control group, and lower incidence of hypoglycemic events as 13.33% than 43.33% in the control group. Their difference was statistically significant(P<0.05). Conclusion Both insulin glargine and intermediate-acting human insulin can effectively control the blood glucose of elderly patients with type 2 diabetes. The former has lower incidence of hypoglycemia, less insulin, and shorter time of blood glucose reaching standard. Elderly patients with type 2 diabetes benefit more.
Objective To compare the clinical efficacy and safety of insulin glargine and intermediateacting human insulin in the treatment of type 2 diabetes in the elderly. Methods A total of 60 elderly patients with type 2 diabetes were randomly divided into control group and observation group, with 30 cases in each group. The control group was treated with intermediate-acting human insulin, and the observation group was treated with insulin glargine. Comparison were made on fasting plasma glucose(FPG) and postprandial 2 h plasma glucose(PPG) before and after treatment, the time of blood glucose reaching the standard, the daily dosage of insulin and the occurrence of hypoglycemia events between the two groups. Results Before treatment, the observation group had FPG and PPG level respectively as(9.19±1.24) and(16.35±3.58) mmol/L, which were(9.22±1.19) and(16.21±3.64) mmol/L in the control group, and the difference was not statistically significant(P>0.05). After treatment, the observation group had FPG and PPG level respectively as(5.98±1.04) and(9.41±1.58) mmol/L, which were(6.23±0.92) and(9.57±1.67) mmol/L in the control group. Both groups had lower FPG and PPG than those before treatment, and the difference was statistically significant(P<0.05). There was no statistically significant difference in FPG and PPG(P>0.05). After treatment, the observation group had shorter time of blood glucose reaching standard as(2.81±0.26) d than(3.24±0.64) d in the control group, less daily dosage of insulin as(0.65±0.07) IU/kg than(0.79±0.06) IU/kg in the control group, and lower incidence of hypoglycemic events as 13.33% than 43.33% in the control group. Their difference was statistically significant(P<0.05). Conclusion Both insulin glargine and intermediate-acting human insulin can effectively control the blood glucose of elderly patients with type 2 diabetes. The former has lower incidence of hypoglycemia, less insulin, and shorter time of blood glucose reaching standard. Elderly patients with type 2 diabetes benefit more.
引文
[1]中华医学会糖尿病学分会.中国2型糖尿病防治指南(2010年版).中国糖尿病杂志, 2012, 20(1):54-109.
[2]Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part1:diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med, 1998, 15(7):539-553.
[3]葛均波,徐永健.内科学.第8版.北京:人民卫生出版社, 2014:733-751.
[4]马朝军.老年2型糖尿病合并心脑血管病变的危险因素探析.中国实用医药, 2016, 11(16):76-77.
[5]谢立兵.老年2型糖尿病低血糖症24例临床分析.中国实用医药, 2011, 6(32):39-41.
[6]王曹锋,蔡文玮,陈谊,等.阿卡波糖控制不佳的老年2型糖尿病患者联合甘精胰岛素或中效胰岛素对血糖的影响.老年医学与保健, 2017, 23(2):105-108.
[7]廖庆斌.甘精胰岛素与阿卡波糖片联合治疗老年糖尿病50例临床观察.重庆医学, 2012, 41(5):477-478.
[8]孔亚坤,耿秀琴,周艳红,等.甘精胰岛素与西格列汀联用治疗口服降糖药控制不佳的老年2型糖尿病的有效性和安全性.中国药师, 2016, 19(4):695-697.
[2]Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part1:diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med, 1998, 15(7):539-553.
[3]葛均波,徐永健.内科学.第8版.北京:人民卫生出版社, 2014:733-751.
[4]马朝军.老年2型糖尿病合并心脑血管病变的危险因素探析.中国实用医药, 2016, 11(16):76-77.
[5]谢立兵.老年2型糖尿病低血糖症24例临床分析.中国实用医药, 2011, 6(32):39-41.
[6]王曹锋,蔡文玮,陈谊,等.阿卡波糖控制不佳的老年2型糖尿病患者联合甘精胰岛素或中效胰岛素对血糖的影响.老年医学与保健, 2017, 23(2):105-108.
[7]廖庆斌.甘精胰岛素与阿卡波糖片联合治疗老年糖尿病50例临床观察.重庆医学, 2012, 41(5):477-478.
[8]孔亚坤,耿秀琴,周艳红,等.甘精胰岛素与西格列汀联用治疗口服降糖药控制不佳的老年2型糖尿病的有效性和安全性.中国药师, 2016, 19(4):695-697.